BOSTON and Durham, N.C. October 20, 2021 —Parexel today joined Kyoto University Hospital to announce a strategic alliance. This innovative collaboration aims to help provide more opportunities for clinical research and produce efficient and productive ways of supporting clinical studies. As part of Parexel’s Alliance Site network — consisting of more than 500 sites and 17,000 investigators across the globe accelerating access to and enrollment of patient populations for clinical trials — Kyoto University Hospital will share their therapeutic areas of expertise and opportunities to contribute to specific areas of research.
“We’re excited about this collaboration and our ability to help drive clinical trial innovation,” said Clare Grace, Ph.D., Chief Patient Officer at Parexel. “Our organizations share a passion and commitment to conduct cutting-edge clinical research to advance the future of medicine and help patients in need.”
“Parexel’s clinical and operational scale dates back more than 20 years in the Asia/Pacific region,” said Shigehiro Miki, Japan General Manager at Parexel. “This collaboration will help us further our efforts to bring new and innovative medicines to market.”
“It is my great pleasure that we have signed an alliance agreement with Parexel,” said Manabu Muto, M.D., Ph.D., Director of Ki-CONNECT, Professor, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University. “We expect that this will be an advantage not only for Ki-CONNECT but also for various other developers. I sincerely hope that many innovative medical treatments will reach the clinical stage based on this alliance.”
CEO: Jamie Macdonald
Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy